Ignite Creation Date:
2024-05-06 @ 12:32 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03786692
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2018-12-21
Brief Title:
Phase II Randomized Trial of CarboplatinPemetrexedBevacizumab- Atezolizumab in Stage IV NSCLC
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Organization Data
Organization:
Fox Chase Cancer Center
Class:
OTHER
Study ID:
TH-138
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fox Chase Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Comprehensive Cancer Network | NETWORK |